Two accepted standards, one decision
PIC/S and the ASEAN Listed Inspection Service are both applied. Knowing which one an application is being assessed against — and saying so in the submission — avoids assembling evidence for the wrong frame.
[ NATIONAL · TH ]
Thailand
A national food and drug administration licensing both manufacturers and importers, with a PIC/S-aligned inspectorate.
What this page does not claim
SPEQ synthesis for orientation. It does not determine what applies to a specific product, and an adopted version can move without this page moving with it. Confirm the instrument in force with the authority before relying on it.
Who regulates here (1)
ASIA-PACIFIC
What makes a requirement binding here
The Drug Act, B.E. 2510 (1967), as amended, which provides the framework for marketing authorisation and post-marketing surveillance of drugs and biologics. The national food and drug administration issued good manufacturing practice regulations and accompanying guidelines in 2011 that follow ASEAN GMP and the PIC/S guide.
Through licences granted under the Drug Act, assessed against one of two accepted standards. The authority applies either the PIC/S guide or the Listed Inspection Service of the Association of South East Asian Nations as the good manufacturing practice standard when deciding whether to grant the relevant licence. That choice of two is unusual and is the thing to establish early: which standard a given application is being read against determines what the evidence has to look like.
WHAT TRANSFERS
PIC/S evidence is legible, and the regional route is a genuine alternative. Thailand participates in PIC/S, so an inspection outcome from another participating authority is recognisable and can support the assessment. The ASEAN listed-inspection route means a manufacturer whose evidence sits in the regional system is not disadvantaged for lacking a PIC/S inspection. SPEQ has not decoded ICH participation for Thailand, so dossier expectations should be confirmed against the authority’s own guidance rather than assumed to follow an ICH-region format.
Operating here
The Drug Act is old and amended
B.E. 2510 dates from 1967 and has been amended repeatedly. Working from the original text is a reliable way to cite a provision that has since moved, so read the Act as amended.
Manufacture and importation under one authority
The same administration licenses both. A company that begins by importing and later manufactures locally is extending an existing relationship rather than starting a new one, which is worth structuring the first licence around.
Regional context is part of the picture
ASEAN harmonisation shapes what the authority accepts and how a submission reads to it. A dossier built purely for a Western market misses the regional vocabulary the assessor uses daily.
What practitioners get wrong
- The choice between the PIC/S guide and the ASEAN listed-inspection route is a real fork, not a formality. Establish which applies before assembling evidence.
- Cite the Drug Act as amended. B.E. 2510 is a 1967 instrument and the unamended text will misstate current provisions.
- SPEQ has not decoded ICH participation for Thailand. Confirm dossier format against the authority’s guidance rather than assuming an ICH-region submission transfers.
- Because manufacture and importation sit with one authority, the import licence a company starts with shapes the manufacturing conversation later. Structure it with that in mind.
Questions about Thailand
What legislation governs medicines in Thailand?
The Drug Act, B.E. 2510 (1967), as amended, which frames marketing authorisation and post-marketing surveillance for drugs and biologics. GMP regulations and guidelines issued in 2011 follow ASEAN GMP and the PIC/S guide.
Which GMP standard does the Thai authority inspect against?
Either the PIC/S guide or the Listed Inspection Service of the Association of South East Asian Nations, applied when granting the relevant licences under the Drug Act. Both are accepted, so establishing which frames a given application matters to how evidence is prepared.
Does a PIC/S inspection from another country satisfy Thailand?
It supports the assessment rather than replacing it. Thailand participates in PIC/S, so an outcome from another participating authority is recognisable, but the licence is granted under the Drug Act by the Thai authority.
ADOPTED, AT A PINNED VERSION
What binds here, and which edition
SPEQ has not decoded a pinned adoption edge here yet. That is a gap in this catalog, not a finding about Thailand: requirements still arrive through the authorities below, and the edition in force is theirs to state.
What influences it
Participation changes which evidence transfers, and which edition of a harmonized guide the local instrument is likely to pin.